Observational studyDrug design, development and therapy2026
Low-Dose Neostigmine at 0.7 Train-of-Four Ratio Safely Accelerates Neuromuscular Recovery: A Prospective Observational Study.
Observational study in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Neostigmine is recommended to reverse the minimal depth of the neuromuscular blockade. However, neostigmine administered at a minimal blockade may cause paradoxical muscle weakness. This study aimed to assess the efficacy and safety of neostigmine administered at a train-of-four (TOF) ratio of 0.7 for neuromuscular recovery. Patients and methods: This prospective observational study included 54 patients who underwent thyroid surgery under intravenous anesthesia. Neostigmine 20 mcg/kg was administered when the TOF ratio spontaneously recovered to 0.7 during surgery. The recovery times were recorded based on the time from a TOF ratio of 0.7 to 1.0 and 0.9. Outcomes were compared with those of patients with spontaneous recovery, including recovery times and incidence of adverse events, such as paradoxical muscle weakness. Results: Neostigmine administration significantly reduced recovery time from a TOF ratio of 0.7 to 1.0 (4.9 vs 10.2 min, Conclusion: Administering 20 mcg/kg neostigmine at a TOF ratio of 0.7 is effective and safe, facilitating neuromuscular recovery without adverse effects. This treatment regimen can enhance surgical workflow efficiency and reduce patient recovery times while maintaining patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.